The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

The frontline combination of ibrutinib with venetoclax was associated with complete response and durable remission for older patients with MCL.

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, ...

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at ...

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.